JP2017528431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528431A5 JP2017528431A5 JP2017502821A JP2017502821A JP2017528431A5 JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5 JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- composition
- active
- metformin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025714P | 2014-07-17 | 2014-07-17 | |
| US62/025,714 | 2014-07-17 | ||
| PCT/US2015/040879 WO2016011335A1 (en) | 2014-07-17 | 2015-07-17 | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528431A JP2017528431A (ja) | 2017-09-28 |
| JP2017528431A5 true JP2017528431A5 (OSRAM) | 2018-08-16 |
Family
ID=55079079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502821A Pending JP2017528431A (ja) | 2014-07-17 | 2015-07-17 | 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170173060A1 (OSRAM) |
| EP (1) | EP3169331A4 (OSRAM) |
| JP (1) | JP2017528431A (OSRAM) |
| KR (1) | KR20170026635A (OSRAM) |
| CN (1) | CN106687119A (OSRAM) |
| AU (1) | AU2015289511A1 (OSRAM) |
| CA (1) | CA2955425A1 (OSRAM) |
| IL (1) | IL250170A0 (OSRAM) |
| WO (1) | WO2016011335A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8999721B2 (en) | 2009-10-23 | 2015-04-07 | Therabrake, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| US20180099001A1 (en) | 2011-04-29 | 2018-04-12 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
| EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN |
| PL3393496T3 (pl) | 2015-12-23 | 2024-04-22 | The Johns Hopkins University | Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych |
| WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
| US10398389B1 (en) | 2016-04-11 | 2019-09-03 | Pricewaterhousecoopers Llp | System and method for physiological health simulation |
| WO2017203367A2 (en) * | 2016-05-22 | 2017-11-30 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
| KR20190121785A (ko) | 2017-02-10 | 2019-10-28 | 이노베이트 바이오파마슈티컬스, 인코포레이티드 | 장 상피의 투과성과 관련된 질환을 치료하기 위한 조성물 및 방법 |
| WO2018204918A1 (en) * | 2017-05-05 | 2018-11-08 | Ardelyx, Inc. | Treatment of hepatic disorders |
| US20200199645A1 (en) * | 2017-09-08 | 2020-06-25 | Control Of Innate Immunity Technology Research Association | Device and method for diagnosis of alzheimer's symptoms |
| KR102282490B1 (ko) * | 2018-01-12 | 2021-07-28 | 주식회사 엠디헬스케어 | 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도 |
| KR102868782B1 (ko) * | 2018-01-12 | 2025-10-13 | (주)메티메디제약 | 만성 염증성 질환의 치료 방법 |
| CA3091308A1 (en) * | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| AU2019232145B2 (en) * | 2018-03-07 | 2024-08-08 | Teagasc - The Agriculture And Food Development Authority | A composition for type II diabetics and for use in providing sustained energy release over time |
| US10803981B2 (en) | 2018-10-15 | 2020-10-13 | James Glenn Norman | Applied artificial intelligence technology for hormone therapy treatment |
| WO2020081369A1 (en) * | 2018-10-15 | 2020-04-23 | James Glenn Norman | Applied artificial intelligence technology for hormone therapy treatment |
| KR102104507B1 (ko) * | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 |
| US12260944B2 (en) | 2019-10-11 | 2025-03-25 | Hoffmann-La-Roche Inc. | Drug dosage determination devices and methods |
| CN115003306A (zh) * | 2020-01-08 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和二肽基肽酶4抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
| CN117056370A (zh) * | 2020-03-19 | 2023-11-14 | 上海太美星云数字科技有限公司 | 医学数据处理方法、装置、设备和存储介质 |
| WO2022243459A1 (en) * | 2021-05-19 | 2022-11-24 | Charité - Universitätsmedizin Berlin | Computer assisted method for the evaluation of cardiac metabolism |
| CN113362925B (zh) * | 2021-06-29 | 2022-04-08 | 山东第一医科大学附属省立医院(山东省立医院) | 一种自动良肢位控制方法及设备 |
| CN114705871A (zh) * | 2022-04-12 | 2022-07-05 | 复旦大学附属中山医院 | 8异前列腺素F2α在重度哮喘诊断中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| AU2004275777A1 (en) * | 2003-09-24 | 2005-04-07 | Combinatorx, Incorporated | Therapeutic regimens for administering drug combinations |
| CA2616806A1 (en) * | 2005-07-28 | 2007-02-08 | Reliant Pharmaceuticals, Inc. | Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof |
| KR101468053B1 (ko) * | 2006-08-31 | 2014-12-02 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템 |
| US8999721B2 (en) * | 2009-10-23 | 2015-04-07 | Therabrake, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| CN110152000A (zh) * | 2011-03-02 | 2019-08-23 | J·深塔格 | 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物 |
| AU2014205553A1 (en) * | 2013-01-08 | 2015-07-09 | Volant Holdings Gmbh | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
-
2015
- 2015-07-17 WO PCT/US2015/040879 patent/WO2016011335A1/en not_active Ceased
- 2015-07-17 CN CN201580050102.7A patent/CN106687119A/zh active Pending
- 2015-07-17 JP JP2017502821A patent/JP2017528431A/ja active Pending
- 2015-07-17 EP EP15822742.1A patent/EP3169331A4/en not_active Withdrawn
- 2015-07-17 CA CA2955425A patent/CA2955425A1/en not_active Abandoned
- 2015-07-17 KR KR1020177004581A patent/KR20170026635A/ko not_active Withdrawn
- 2015-07-17 AU AU2015289511A patent/AU2015289511A1/en not_active Abandoned
-
2017
- 2017-01-17 US US15/407,394 patent/US20170173060A1/en not_active Abandoned
- 2017-01-17 IL IL250170A patent/IL250170A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528431A5 (OSRAM) | ||
| ES2307463T3 (es) | Forma de dosificación de combinación que contiene un agente reductor del colesterol, un inhibidor de la renina-angiotensina, y aspirina. | |
| KR102103426B1 (ko) | 당뇨병 신규 발병 저감용 조성물 | |
| JP2015503593A5 (OSRAM) | ||
| EP3581173B1 (en) | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation | |
| HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
| JP2015522029A5 (OSRAM) | ||
| JP5453434B2 (ja) | エタノールの影響に対する耐性を有するオピオイドではないｐＨ依存の制御放出の医薬組成物 | |
| JP2019048843A5 (OSRAM) | ||
| JP2017528516A5 (OSRAM) | ||
| JP2015503590A5 (OSRAM) | ||
| US20110311631A1 (en) | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients | |
| RU2018120726A (ru) | Комбинации с гемкабеном для лечения заболеваний сердечно-сосудистой системы | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| ES2623176T3 (es) | Composición farmacéutica de memantina | |
| JP2007119479A5 (OSRAM) | ||
| KR20110128869A (ko) | 중성 비닐 중합체 및 부형제를 포함하는 코팅을 이용하는, 에탄올의 영향에 대한 내성을 갖는 제어 방출 제약 조성물 | |
| JP2010539196A (ja) | エタノールの影響に対して耐性を有する非オピオイド薬のｐＨ依存性制御放出医薬組成物 | |
| Bader et al. | Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro | |
| KR20090114325A (ko) | 약제학적 제제 | |
| RU2014127884A (ru) | Способы лечения сердечно-сосудистого нарушения | |
| ES2299072T3 (es) | Procedimiento para la preparacion de formas medicamentosas con perfil de liberacion de principio activo estable. | |
| MXPA04006780A (es) | Formulaciones farmaceuticas de pravastatina y metodos para usarlas. | |
| EP2197439A2 (en) | Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid | |
| Kim et al. | Efficacy of gastro-retentive forms of ecabet sodium in the treatment of gastric ulcer in rats |